On August 28, Rejing Bio(688068) issued an announcement that it recently received a request from a joint venture company for an innovative drugA progress report on the Phase I clinical study of SGC001 injection. The project has completed a Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly. Clinical observations of all subjects have been completed, and the clinical study was unblinded on August 27.

SGC001 injection, developed jointly by Sungene's R&D team and other institutions, is indicated for the emergency treatment of patients with acute myocardial infarction. The drug's clinical trial application has been approved by the FDA and CDE, and it received FDA Fast Track designation in March 2025. Currently, complete efficacy and safety information from the Phase Ib trial will be disclosed in the official data analysis report, and will not have a significant impact on the company's performance in the short term.

In the first quarter of 2025, Regen Bio achieved revenue of 93.24 million yuan and net profit attributable to shareholders of the parent company was -24.01 million yuan.

https://finance.eastmoney.com/a/202508283498069228.html